Cubist Systematic Strategies LLC Takes Position in United Therapeutics Co. (UTHR)
Cubist Systematic Strategies LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,882 shares of the biotechnology company’s stock, valued at approximately $552,000.
Other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in shares of United Therapeutics by 2.8% in the 2nd quarter. Bank of America Corp DE now owns 99,674 shares of the biotechnology company’s stock worth $11,277,000 after acquiring an additional 2,724 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $600,000. AMP Capital Investors Ltd lifted its stake in shares of United Therapeutics by 1.2% in the 2nd quarter. AMP Capital Investors Ltd now owns 57,534 shares of the biotechnology company’s stock worth $6,511,000 after acquiring an additional 700 shares during the period. Flinton Capital Management LLC lifted its stake in shares of United Therapeutics by 26.0% in the 2nd quarter. Flinton Capital Management LLC now owns 40,208 shares of the biotechnology company’s stock worth $4,550,000 after acquiring an additional 8,288 shares during the period. Finally, Laurion Capital Management LP lifted its stake in shares of United Therapeutics by 85.9% in the 2nd quarter. Laurion Capital Management LP now owns 3,332 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 1,540 shares during the period. 95.83% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Christopher Causey sold 810 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the completion of the sale, the director now directly owns 1,555 shares of the company’s stock, valued at $185,045. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,240 shares of the stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $113.07, for a total transaction of $366,346.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,100 shares of company stock valued at $977,508. Company insiders own 8.20% of the company’s stock.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, beating the consensus estimate of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business had revenue of $444.50 million during the quarter, compared to analyst estimates of $368.63 million. During the same period in the prior year, the business earned $4.37 earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. equities analysts predict that United Therapeutics Co. will post 14.77 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. BidaskClub lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. TheStreet lowered shares of United Therapeutics from a “b” rating to a “c+” rating in a research note on Thursday, September 6th. Wedbush set a $253.00 price target on shares of United Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 4th. HC Wainwright set a $95.00 target price on shares of United Therapeutics and gave the company a “hold” rating in a research note on Monday, August 13th. Finally, Credit Suisse Group lowered shares of United Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $138.86.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading: Short Selling Stocks and Day Traders
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.